

Dated: March 9, 2023.

**Terrance Perry,**

*Chief Grants Management Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023-05256 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH23-003, Conducting Public Health Research With Universities in Thailand; Amended Notice of Closed Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH23-003, Conducting Public Health Research with Universities in Thailand; April 12, 2023, 9 a.m.–2:30 p.m., EDT, teleconference, in the original **Federal Register** Notice. The meeting was published in the **Federal Register** on March 2, 2023, Volume 88, Number 41, page 13121.

The meeting is being amended to add a Notice of Funding Opportunity number and should read as follows:

*Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH20-002, Malaria Operations Research to Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; and GH23-003, Conducting Public Health Research with Universities in Thailand.*

The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:** Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Road NE, Mailstop H21-9, Atlanta, Georgia 30329-4027; Telephone: (404) 639-4796; Email: [HShoob@cdc.gov](mailto:HShoob@cdc.gov).

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023-05297 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Clinical Laboratory Improvement Advisory Committee

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Clinical Laboratory Improvement Advisory Committee (CLIAC). This meeting is open to the public, limited only by the number of webcast lines available. Time will be available for public comment.

**DATES:** The meeting will be held on April 12, 2023, from 11 a.m. to 5:30 p.m., EDT, and April 13, 2023, from 11 a.m. to 5 p.m., EDT.

**ADDRESSES:** This is a virtual meeting. Meeting times are tentative and subject to change. The confirmed meeting times, agenda items, and meeting materials, including instructions for accessing the live meeting broadcast, will be available on the CLIAC website at <https://www.cdc.gov/cliac>. Check the website on the day of the meeting for the web conference link.

**FOR FURTHER INFORMATION CONTACT:** Heather Stang, MS, Senior Advisor for Clinical Laboratories, Division of Laboratory Systems, Office of Laboratory Science and Safety, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia 30329-4027. Telephone: (404) 498-2769; Email: [HStang@cdc.gov](mailto:HStang@cdc.gov).

#### **SUPPLEMENTARY INFORMATION:**

*Purpose:* The Clinical Laboratory Improvement Advisory Committee (CLIAC) is charged with providing scientific and technical advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; the Director, CDC; the Commissioner, Food and Drug Administration (FDA); and the Administrator, Centers for Medicare &

Medicaid Services (CMS). The advice and guidance pertain to general issues related to improvement in clinical laboratory quality and laboratory medicine and specific questions related to possible revision of the Clinical Laboratory Improvement Amendments of 1988 (CLIA) standards. Examples include providing guidance on studies designed to improve quality, safety, effectiveness, efficiency, timeliness, equity, and patient-centeredness of laboratory services; revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards on medical and laboratory practice; and the modification of the standards and provision of non-regulatory guidelines to accommodate technological advances, such as new test methods, the electronic transmission of laboratory information, and mechanisms to improve the integration of public health and clinical laboratory practices.

*Matters To Be Considered:* The agenda will include agency updates from CDC, CMS, and FDA. Presentations and CLIAC discussions will focus on reports from two CLIAC workgroups: the CLIA Regulations Assessment Workgroup and the CLIA Certificate of Waiver and Certificate for Provider-performed Microscopy Procedures Workgroup, and on the laboratory's role in advancing health equity. Agenda items are subject to change as priorities dictate.

#### **Public Participation**

It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments pertinent to agenda items.

*Oral Public Comment:* Public comment periods for each agenda item are scheduled immediately prior to the Committee discussion period for that item. In general, each individual or group requesting to present an oral comment will be limited to a total time of five minutes (unless otherwise indicated). Speakers should email [CLIAC@cdc.gov](mailto:CLIAC@cdc.gov) or notify the contact person above (see **FOR FURTHER INFORMATION CONTACT**) at least five business days prior to the meeting date.

*Written Public Comment:* CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, it is requested that comments be submitted at least five business days prior to the meeting date so that the comments may be made available to the Committee for their consideration and public distribution. Written comments should be submitted by email to [CLIAC@cdc.gov](mailto:CLIAC@cdc.gov) or to the contact person above. All written comments will be